Team siliconindia

• DPIIT and Roche India join forces to support startups in oncology, neurology, rare diseases, and more.
• Startups will receive access to international experts, advanced tech, and validation platforms.
• The partnership emphasizes regulatory guidance, IP support, HEOR, GCP, and patient engagement.

In a significant step toward strengthening India’s health innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, has signed a Memorandum of Understanding (MoU) with Roche Products (India) Pvt. Ltd. The collaboration aims to support DPIIT-recognized startups operating in critical therapeutic domains such as oncology, neurology, ophthalmology, haematology, and rare diseases.

The MoU was formally signed by Dr. Sumeet Jarangal, Director, DPIIT, and Smt. Rajwinder Mehdwan, Managing Director, Roche India, in the presence of senior officials from both organizations.

Also Read: The Rise of Personalized Nutrition Plans in Transforming Preventive Healthcare

Under the partnership, Roche India will provide expert mentorship, facilitate pilot and validation studies, and offer access to advanced technologies, global platforms, and essential infrastructure to help scale innovations.

Joint Secretary, DPIIT, Shri Sanjiv, emphasized the importance of industry–startup collaboration to bring disruptive healthcare solutions to market. He highlighted additional support in regulatory guidance, IP protection, and alignment with global health standards. Capacity-building in areas like Health Economics and Outcomes Research (HEOR), Good Clinical Practices (GCP), and patient engagement will also be prioritized.

Smt. Mehdwan described the MoU as a collaborative journey to empower healthtech startups in building patient-centric, locally relevant solutions. The partnership underscores DPIIT’s commitment to fostering inclusive innovation and establishing India as a global healthtech leader.